

Special Issue

Cell-Free Nucleic Acids as Diagnostic Tools

Message from the Guest Editors

Historically, blood samples have been used to assess dynamic changes in clinically relevant biomolecules to diagnose disease. Discoveries leading to the identification of cell-free (cf) nucleic acids (NAs) in liquid biopsies have opened possibilities in predicting future disease as cfNAs can not only be biomarkers but also mediators or regulators of pathophysiological processes. Intriguingly, unlike other biomolecules such as SNP profiles from blood, and circulating molecules such as mRNAs, microRNAs, and circRNAs, cfDNAs present dynamic changes over the lifetime, and possibly across generations.

Guest Editors

Prof. Dr. Anandwardhan A. Hardikar

School of Medicine, Western Sydney University, Campbelltown, NSW 2751, Australia

Dr. Mugdha Joglekar

Diabetes and Islet Biology Group, School of Medicine, Western Sydney University, Penrith, Australia

Deadline for manuscript submissions

closed (10 January 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/107750

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2
(Genetics (clinical))